2024 FUNDING ROUND
SHAPE THE FUTURE OF CONSUMER HEALTH CARE: EXCLUSIVE INVESTMENT OPPORTUNITY
Maxwellia is on the verge of something extraordinary…and you could be part of it.
• Over the past 12 months, we've evolved from a one-brand start-up to a scaling consumer healthcare company with a portfolio of 4 incredible women's health brands.
• Our products are stocked by the biggest pharmacy chains in the UK, including Boots, Superdrug, Tesco, and Asda.
• With 3X revenue growth year-on-year and a qualified pipeline of innovative products, we are one of the UK's most exciting consumer healthcare companies with a formidable reputation for pushing boundaries.
WHAT WE DO
We take proven prescription drugs through a complex regulatory process, turning them into household medicine brands that can be bought over the counter at pharmacies.
This reclassification process is called ‘switching’, and as the only company dedicated to doing it in the UK, we’re pretty good at it…in fact, our CEO literally wrote the book on it!
The aim of switching is to widen access medicines getting them into the hands of the people that need them.
WHY INVEST?
• The UK OTC market is growing and is on track to be worth £4bn by 2030 (1)
• Pharmacy is recognised as one of the greatest strengths of the health service in the recent government review of the NHS (2)
• 3 in 4 adults want to access more medicines from pharmacy without prescription (3)
• A 5% reduction in NHS prescribing due to switching could save £1.4bn in avoidable NHS costs (2) driving further incremental value into the OTC market
• The Reclassification Alliance was set up in 2023 led by MHRA, the UK regulator in collaboration with the NHS to specifically look at how switching can be leveraged to improve the efficiency for the NHS.
The time is now; the ‘switching’ wave is coming and Maxwellia is poised to deliver the next generation of medicine cabinet essentials. Do you want to be part of it?
JOIN OUR EXCLUSIVE 100 CLUB
We’re looking for 100 investors to invest in our £2m fund raise to enable Maxwellia to scale. The raise is supported by further investments from our existing institutional shareholder base.
As part of this inner circle, you’ll be supporting the next wave of our brand innovation, helping us scale beyond our already incredible success. With a lean but expert team, we’ve proven that we can turn ambition into results. Now, we need you to help us take it to the next level.
View our investment profile and take the next steps to invest in Maxwellia via KickStart Capital.
Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment.
ABOUT YOUR EIS INVESTMENT
Your investment in Maxwellia can benefit from the Enterprise Investment Scheme (EIS). EIS offers a range of benefits to investors:
Maxwellia is a Knowledge-Intensive Company
1. Income Tax Relief
Investors can claim up to 30% relief on investments in EIS-qualifying shares, up to £1 million annually (£2 million for Knowledge-Intensive Companies). The investment must be held for at least 3 years, and investors can "carry back" the relief to the previous tax year.
2. Capital Gains Tax (CGT) Freedom
No CGT is payable on shares sold after 3 years if income tax relief was received and not withdrawn.
3. CGT Deferral Relief
Investors can defer CGT on gains from other assets by investing in EIS shares. The deferral lasts as long as the EIS shares are held.
4. Loss Relief
If shares are sold at a loss, the loss can be offset against capital gains or income, reducing the investment risk.
5. Business Relief for Inheritance Tax (IHT)
EIS shares may qualify for 100% IHT relief after 2 years, potentially eliminating inheritance tax on the investment.